This company listing is no longer active
Kolinpharma Balance Sheet Health
Financial Health criteria checks 6/6
Kolinpharma has a total shareholder equity of €8.4M and total debt of €8.8M, which brings its debt-to-equity ratio to 105.3%. Its total assets and total liabilities are €22.1M and €13.8M respectively. Kolinpharma's EBIT is €970.9K making its interest coverage ratio 4. It has cash and short-term investments of €9.6M.
Key information
105.3%
Debt to equity ratio
€8.80m
Debt
Interest coverage ratio | 4x |
Cash | €9.55m |
Equity | €8.36m |
Total liabilities | €13.78m |
Total assets | €22.14m |
Recent financial health updates
We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its Debt
Jun 08These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably Well
Nov 22Recent updates
Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On Capital
Jun 17What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?
Dec 01An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% Undervalued
Aug 25We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its Debt
Jun 08Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?
May 21Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?
May 03Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E Ratio
Apr 13What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?
Feb 20Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Dec 28These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably Well
Nov 22Financial Position Analysis
Short Term Liabilities: KIP's short term assets (€15.6M) exceed its short term liabilities (€5.3M).
Long Term Liabilities: KIP's short term assets (€15.6M) exceed its long term liabilities (€8.4M).
Debt to Equity History and Analysis
Debt Level: KIP has more cash than its total debt.
Reducing Debt: KIP's debt to equity ratio has reduced from 201.5% to 105.3% over the past 5 years.
Debt Coverage: KIP's debt is well covered by operating cash flow (31.7%).
Interest Coverage: KIP's interest payments on its debt are well covered by EBIT (4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/11/01 14:49 |
End of Day Share Price | 2023/09/27 00:00 |
Earnings | 2022/12/31 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kolinpharma S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Luigi Tardella | EnVent Capital Markets Limited |
Luisa Primi | IR Top Consulting S.r.l. |